Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial

BACKGROUND: Neuroendocrine tumors (NETs) are the second most common gastrointestinal malignancy after colon cancer. Up to 90% of patients with NETs develop liver metastases, which are a major determinant of symptoms and survival. Current guidelines recommend embolotherapy for progressive or symptoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, James X., Wileyto, E. Paul, Soulen, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050671/
https://www.ncbi.nlm.nih.gov/pubmed/30016989
http://dx.doi.org/10.1186/s13063-018-2782-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050671/
https://www.ncbi.nlm.nih.gov/pubmed/30016989
http://dx.doi.org/10.1186/s13063-018-2782-5

Ejemplares similares